**Unrecognised Burden: High Prevalence and Clinical Impact of Fibromyalgia in Functional Motor Disorder**

Tereza Serranová MD, PhD[1]†, Lucia Nováková MD[1], Martin Jirásek[2], Barbora Křupková MD[1], Prof. Evžen Růžička MD, DrSc[1], Prof. Michele Tinazzi MD, PhD[4], Tomáš Sieger PhD[1,3]

1 Charles University, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czechia

2 Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czechia.

3 Department of Cybernetics, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czechia.

4 Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy

†**Corresponding author**: Tereza Serranova, MD, Dept. of Neurology, 1st Faculty of Medicine and General University Hospital in Prague, Kateřinská 30, Prague, 128 08, Czechia. Email: tereza.serranova@vfn.cz

**Word count:** Abstract 247 words; 3459 words including Introduction, Method, Results and Discussion; 3 Tables; 54 References

**Short running title:** Fibromyalgia in FMD

**Key words:** functional neurological disorder; fibromyalgia, prevalence, quality of life, medication

**Ethical consideration:** The study complies with the Declaration of Helsinki's ethical standards. The

study was approved by the local ethics committee, and all participants gave their written consent to

take part in the study 53/23 Grant AZV VES 2024.

**Conflict of Interest Statement:** The authors declare that there are no conflicts of interest relevant to

this work.

**Data Availability Statement:** The data analysed in the present study are available upon reasonable

request.

36
37
38  **Funding:** This study was supported by the Czech Ministry of Health (NW24-04-00456 and MH CZ–

39  DRO-VFN00064165) and National Institute for Neurological Research (Programme EXCELES, ID

40  Project No. LX22NPO5107) and by the Czech Ministry of Education, Youth and Sports /EU ERDF-

41  Project Brain Dynamics, No. CZ.02.01.01/00/22_008/0004643.

**Abstract:**

**Background:** Fibromyalgia is a chronic pain disorder, affecting 2-3% of the population, characterised by widespread pain, fatigue, sleep and cognitive symptoms. Despite symptom overlap between functional motor disorder (FMD) and fibromyalgia, the prevalence of fibromyalgia in FMD and its impact on health-related quality of life (HRQoL) remain unclear.

**Objectives:** To assess the prevalence of fibromyalgia in FMD using the 2016 American College of Rheumatology diagnostic criteria and to evaluate its impact on HRQoL.

**Methods:** A total of 139 consecutive patients with clinically established FMD (115 females, mean age 44.6 (SD 11.3) years) completed Fibromyalgia Survey Questionnaire, subjective motor symptoms and HRQoL assessments. Motor symptoms were objectively rated using the Simplified FMD Rating Scale (S-FMDRS). Major physical illnesses, neurological, and psychiatric comorbidities, and the use of centrally acting and nociceptive pain medication was recorded.

**Results:** Fibromyalgia was present in 44.6% of FMD patients (95%CI: 36.2–53.3%). Those with fibromyalgia had higher S-FMDRS scores ($p < 0.01$), lower HRQoL ($p < 0.001$), more frequent use of centrally acting and nociceptive pain medication ($p < 0.01$). Fibromyalgia severity was positively correlated with both subjective motor symptom severity ($p < 0.01$) and S-FMDRS ($p < 0.05$). Higher fibromyalgia severity ($p < 0.001$), S-FMDRS ($p < 0.001$), and psychiatric comorbidity ($p < 0.001$) were independent predictors of lower HRQoL.

**Conclusions:** In this study, fibromyalgia was common in FMD and associated with more severe motor symptoms, greater medication use and reduced quality of life, highlighting the importance of recognising and managing fibromyalgia in FMD.

Functional motor disorder (FMD) is a common source of neurological disability [1]. Its

monetary impact is among the top healthcare-related expenditures for chronic illnesses [2]. People

with FMD almost invariably present with numerous non-motor symptoms, such as pain, fatigue, and

cognitive and psychological symptoms, which have a significant impact on health-related quality of

life (HRQoL) [3]. Pain is one of the key symptoms of FMD [4,5].  Pain has been linked to greater

FMD severity and reduced quality of life [6,7]. For instance, the presence of significant pain can

prevent people with FMD from involvement in physical therapy. Assessing and treating pain is

increasingly recognised as an integral part of managing FMD [8,9].

Fibromyalgia is a common chronic pain condition characterised by widespread pain that

affects between 2-3% of the general population and has a substantial impact on people's lives [10,11].

Fibromyalgia and FMD share common non-motor symptoms, including fatigue, cognitive issues,

sleep disturbances, and headaches [7,12–14]. The importance of these non-motor symptoms has been

recognised by the current diagnostic criteria, which abandoned the objective assessment of tender

points, and the diagnosis is based on self-reported widespread pain and other symptoms [10,15].

According to a recent systematic review on pain in functional neurological disorder, the

prevalence of fibromyalgia in different cohorts of people with functional neurological disorder has

been reported to range from 4% to 18% across multiple studies, with a pooled prevalence of

approximately 10% [5]. This rate is thus higher than estimates for the general population. However, it

is likely still underestimated as the reported cases were not based on clinical assessment using the

current criteria for fibromyalgia and establishing fibromyalgia was not the focus of those studies [16–

21]. Given that fibromyalgia is frequently unrecognised and underdiagnosed, we hypothesised its true

prevalence in FMD may be even higher and associated with a poorer HRQoL, more severe motor

symptoms, higher multimorbidity burden, and increased medication use.

To address this, we systematically assessed the prevalence of fibromyalgia in a consecutive

cohort of patients with FMD using the current diagnostic criteria.  In addition, we collected detailed

data on motor symptoms severity, neurological and systemic comorbidities, medication use, HRQoL.

We then compared patients with and without fibromyalgia to explore the clinical correlates of

comorbid fibromyalgia in FMD. Finally, we examined the association between the presence and the

severity of fibromyalgia symptoms and HRQoL, to determine whether fibromyalgia independently

predicts poorer quality of life in this population.

**Materials and methods**

We recruited 163 consecutive patients (133 females, mean age 44.3 [standard deviation, SD=11.3,

range 15 to 72] years; mean disease duration 6.9 [SD 7.3, range 0 to 40] ) years with clinically

definite FMD according to Gupta and Lang criteria between June 27, 2022, and February 23, 2024,

from the specialized outpatient service for FMD at the Neurology Department of the First Faculty of

Medicine and General University Hospital [22, 23]. The diagnosis of FMD was based on detailed

clinical interviews and examination by a neurologist with experience with FMD (TS, LN) based on

positive signs of internal inconsistency of the movement within one task or in between tasks [24].

Exclusion criteria were defined as: age <18 years, inability to complete questionnaires because of

language difficulties, severe learning disabilities or cognitive impairment, major psychiatric

comorbidity (e.g., psychosis, substance abuse). Comorbid neurological or rheumatological conditions

were not exclusion criteria for the study participation.

*Objective assessment of motor symptoms*

The motor symptoms were classified as functional weakness, tremor, dystonia, myoclonus,

gait disorder, or speech disorder.  Dominant (most severe and/or most frequent motor symptom) and

additional motor symptom types (i.e. tremor, dystonia, gait disorder, myoclonus, and weakness) were

identified. Each patient's number of different motor symptoms was used as a proxy measure for motor

disorder complexity.

The severity of the motor disorder was assessed using The Simplified Functional Movement

Disorder Rating Scale (S-FMDRS) [25]. The presence or absence of abnormal movement at each of

the seven body regions was recorded and rated according to symptom severity and duration

(maximum score: 54). Gait aid score (10m minimal distance) was evaluated as normal gait = 0,

abnormal gait no need for assistance or walking aids = 1, assistance or walker or crutches needed = 2,

wheelchair dependent = 3) [7].

*Fibromyalgia diagnosis*

The 2016 Fibromyalgia Survey Questionnaire was used to assess fibromyalgia based on the

2016 revisions to the 2010/2011 American College of Rheumatology (ACR) diagnostic criteria

[15,26]. Fibromyalgia Survey Questionnaire evaluates the Widespread Pain Index (WPI) and

Symptom Severity Scale (SSS), yielding a Fibromyalgia Severity Score (FSS). The WPI ranges from

0 to 19. The SSS score evaluates the severity of fatigue, unrefreshing sleep, cognitive symptoms,

headaches, abdominal pain or cramps, and depression and ranges from 0 to 12. To meet the criteria

for fibromyalgia (FM) diagnosis, an individual must have a WPI of 7 or higher and a SSS score of 5

or higher, or if the WPI is between 4 and 6, the SSS score must be 9 or higher [15]. In addition, the

individual must experience generalised pain, defined as pain in at least four of five regions, with

symptoms persisting for at least three months. To ensure accuracy, a back-translated version of the

questionnaire was developed with input from bilingual experts and subject-matter specialists.

*Subjective assessment of motor symptoms severity and HRQoL*

All patients self-evaluated their motor symptom severity on a 3-point Likert scale (not

bothered at all = 0, bothered a little = 1, bothered a lot = 2) according to the adjusted Patient-Health

Questionnaire (PHQ-15) [27]. In addition to PHQ-15 items assessing weakness, motor coordination

impairment and gait disorder, we added one item assessing tremor and jerks and one item assessing

abnormal postures or spasms. The total score (subjective motor symptoms severity, SMSS, range 0-

10) was calculated [7].

HRQoL was assessed using the 12-Item v2 Short Form Health Survey (SF-12) [28]. Physical

Functioning, Role Limitations (both Physical and Emotional), Social Functioning, Pain, Mental

Health, Vitality and General Health are HRQoL domains reflected in SF-12 (total score 12-44).

*Clinical assessment of comorbidities and medication.*

All patients were interviewed for the presence of typical symptoms of migraine and restless

legs syndrome, and the current diagnostic criteria were applied to establish the diagnoses. The

presence of comorbidities including: neurological comorbidities (radicular pain, polyneuropathy,

infectious disease, essential tremor, Parkinson's disease, dystonia, stroke, demyelinating disease,

neuromuscular disorder, epilepsy or other), physical health comorbidities (arterial hypertension,

diabetes mellitus, cardiovascular disease, dyslipidaemia, thyroid disorders, asthma, gastrointestinal

disorder, rheumatic disease, autoimmune disease, gynaecological and reproductive disorders, history

of malignancy, obesity) was recorded based on reliable medical report review. Given the absence of

systematic psychiatric assessments in all patients, the presence of psychiatric comorbidity was

recorded dichotomously (present/absent), based on medical documentation, clinical history, screening

during neurological examination, and responses to self-report questionnaires assessing depression and

anxiety.

The use of centrally acting and nociceptive medications including gabapentin, pregabalin,

selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRI)

e.g., venlafaxine, serotonin antagonist and reuptake inhibitors (SARI), noradrenergic and specific

serotonergic antidepressants (NaSAs), tricyclic antidepressants (TCAs), bupropion, dopamine

agonists, antihistamines, dopamine antagonists, benzodiazepines, opioids, anticonvulsants,

cyclobenzaprine, nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, triptans and

medicinal cannabis, was recorded for all participants.

Statistics: The Fisher test was used to test independence in contingency tables. The Wilcoxon

exact rank test was used to test group differences in continuous and discrete measures [29]. Pearson

correlation was used to study the relationship between WPI and motor symptom severity measures.

ANOVA was used to test how FSS differed between patients who used different gait aids. Poisson

regression was used to study how the number of motor phenotypes was related to the FSS. A linear

model was used to find out whether SF-12 could be explained using the combination of FSS, S-

FMDRS, lifelong psychiatric comorbidity, multimorbidity, overall medication use, age, and sex. The

Holm method was used to correct for the number of tests performed within categories (motor

phenotypes, motor symptoms measures, medication, and comorbidities) [30].

Ethical consideration: The study complies with the Declaration of Helsinki's ethical

standards. The study was approved by the local ethics committee, and all participants gave their

written consent to take part in the study 53/23 Grant AZV VES 2024.

**Results**

In 24 out the 163 patients recruited, key data were missing (SF-12 in 12 of them, QPC in 15,

SMSS, FPH1 and STAI.X2 in 10, etc.), so we restricted our sample to 139 patients with FMD (115

females, mean age 44.6 [standard deviation, SD=11.3, range 15 to 72] years; mean disease duration:

6.9 [SD 7.3, range 0 to 40] years).

*Prevalence of fibromyalgia in FMD*

In the analysed sample of 139 FMD patients, 62 patients fulfilled the diagnostic criteria for

fibromyalgia, i.e. the prevalence of fibromyalgia was 44.6% (95% CI (36.2, 53.3) %).

Patients with fibromyalgia (FM+) and patients without fibromyalgia (FM-) did not differ significantly

in age, sex, age at disease onset, or disease duration (see Table 1 for details).

*Between group comparison of FM+ versus FM- patients*

FM+ patients had decreased HRQoL compared to those without FM (median values 20 vs.

24, range 12 to 32 vs. 14 to 42, W=3480, *p* < 0.001) *(also in Table 2).*

While there was a significant association between the main motor phenotype and the presence

of fibromyalgia (Fisher test *p* = 0.026), evaluation of individual phenotypes present either as main or

additional did not reveal any significant associations with fibromyalgia after correction for multiple

comparisons across the six phenotypes. FM+ patients showed higher SFMDRS scores (*p* = 0.016),

more frequent gait disturbances (*p* = 0.026), greater reliance on gait aids (*p* = 0.026), and a higher

number of motor phenotypes (*p* = 0.026). Subjective motor symptom severity was also greater in

FM+ (*p* < 0.001). Gait disorder and instability were relatively more common, and weakness less

common, in FM+ patients (both *p* = 0.065), though overall phenotype frequencies were similar across

groups (see Table 2 for details).

The total number of comorbid physical illnesses and neurological comorbidities, migraine,

and RLS frequencies did not differ significantly between FM+ and FM- groups (all *p* > 0.05; see

Table 3 for details and Supplementary Table 1 for Neurological comorbidities and Supplementary

Table 2 for comorbid major physical illnesses).

FM+ patients used significantly more medications than FM− patients (*p* = 0.012). They more

frequently received drugs with some efficacy in fibromyalgia (amitriptyline, cannabinoids, tramadol;

$p = 0.012$) and nociceptive painkillers ($p = 0.012$), while no group differences were observed for other

drug classes, including antidepressants, benzodiazepines, opioids (see Table 3 for details).

*Correlation analysis of FSS with objective and subjective motor symptom severity measures*

Objective measures: S-FMDRS correlated with FSS (the sum of WPI+SS score) *(r = 0.20, t*

(137) = 2.38, *p* = 0.019). On average, the number of motor phenotypes was greater for higher FSS

(Poisson regression $\chi^2(1) = 4.12$, *p* = 0.04). FSS differed between patients using different gait aids

(those using no gait aids, the mean FSS was 14.9 (range 1 to 30), in those using crutch 17.9 (range 5

to 31), and in those using a wheelchair 18.3 (range (16 to 22) (ANOVA *F* (1,137) = 5.0, *p* = 0.027).

There was a strong relation between subjective assessment of motor symptom severity, i.e. SMSS and

FSS both in FM- patients (*r* = 0.71, *t* (75) = 8.58, *p* <0.001) and in FM+ patients (*r* = 0.34, *t* (60) =

2.85, *p* = 0.006).

*Predictors of the HRQoL*

SF-12 could be partially explained by the combined effect of FSS, S-FMDRS, and lifelong

psychiatric comorbidity (an increase of each of them was, on average, associated with worsening of

HRQoL, FSS: an increase of 10 points was associated with SF-12 worsening by 4.5 points, *t* (135) = -

8.03, *p* < 0.001; S-FMDRS: an increase of 10 points was associated with SF-12 worsening by 1.6

points, *t* (135) = -3.62, *p* < 0.001; psychiatric comorbidity: their presence resulted in decrease of SF-

12 by 3.2, *t* (135) = -4.40, *p* < 0.001; adjusted $R^2 = 0.47$).

**Discussion**

This is the first study to apply the 2016 ACR criteria in a well-characterised consecutive

sample of patients with FMD, revealing a very high prevalence of comorbid fibromyalgia. The

presence of fibromyalgia was associated with lower HRQoL and worse subjectively and objectively

rated motor symptom severity and increased use of medication with central effect and medication

used for nociceptive pain.

With 44.6% of FMD patients meeting the criteria for fibromyalgia, we found a prevalence at

least ten times higher than that reported in the general population [10]. The prevalence of

fibromyalgia diagnosed using the current diagnostic criteria in this study was also much higher than in

the studies that reported fibromyalgia cases in various cohorts of patients with functional neurological

disorders [16–20]. The frequency of previously reported fibromyalgia diagnoses varied from 7/176

(4%) patients in FMD cohorts to 6/56 (16%) [16–20]. These studies, however, did not systematically

assess fibromyalgia using the current diagnostic criteria, relying instead on retrospective chart

reviews. This likely contributed to underrecognition of the condition, highlighting that unless

standardised criteria are actively applied, fibromyalgia may remain frequently overlooked [31].

High frequency of fibromyalgia using the current criteria has been reported in numerous

conditions, including other somatic symptom disorders such as chronic fatigue syndrome [32]; other

pain conditions, including migraine [33–35] or disorders associated with nociceptive pain, such as

rheumatoid arthritis [33]. In our cohort, however, the multimorbidity, including neurological

conditions (including migraine and RLS), did not differ between patients with and without

fibromyalgia, and we did not find an association between multimorbidity and fibromyalgia severity.

This finding suggests that fibromyalgia is not primarily associated or driven by comorbidities.

Available epidemiological data suggest that FM (2-8% in the general population) is more

prevalent than functional neurological disorder (80-140 per 100,000) [36]. Although many people

seen in chronic pain services have a history of functional neurological disorder (17%) [37], there is a

lack of knowledge of the prevalence of FMD in fibromyalgia. While people with fibromyalgia present

with increased frequency of neurologic signs and symptoms, including motor abnormalities, specific

tests for establishing FMD (i.e. tests demonstrating inconsistencies such as Hoover's sign or

distractibility) were not performed [38].

FMD patients with fibromyalgia presented with more severe motor symptoms measured

objectively using the S-FMDRS and a higher number of motor phenotypes. Patients with

fibromyalgia had a greater frequency of gait disturbances and increased reliance on gait aids such as

wheelchairs and crutches. Significant difference was also found in subjectively reported motor

symptom severity, which was higher in the fibromyalgia group. These findings align with previous

observations from other studies, which found that severity in motor and non-motor symptoms is

highly cross-correlated in FMD patients and further support a hypothesised shared mechanism of the

two conditions [7,39]. Several studies reported a lack of association of a particular phenotype and

non-motor symptoms profile [7,40]. Similarly, there was no significant association of fibromyalgia with a specific motor phenotype in this study. The findings from this study suggest that the presence of fibromyalgia should be systematically assessed in all FMD patients, particularly those with more severe motor involvement.

We found a significant impact of fibromyalgia on HRQoL. FMD patients with fibromyalgia reported lower HRQoL, even after correction for depression/anxiety. This finding is in line with previous reports on the impact of pain and other non-motor symptoms on HRQoL and it highlights the importance of addressing them in the management [3,7] As the presence of self-reported non-motor symptoms is part of the current diagnostic criteria for fibromyalgia, we did not investigate symptoms such as fatigue, depression, anxiety or sleep separately. There was a positive association between fibromyalgia severity and subjectively and objectively assessed motor symptoms. However, we found no significant difference in multimorbidity between FMD patients with and without fibromyalgia, suggesting that the presence of fibromyalgia is not primarily driven by other common comorbid conditions.

Patients with fibromyalgia used a greater number of centrally acting and pain medications compared to patients without fibromyalgia. While a significant proportion of patients with fibromyalgia (58 %) was on medication with some evidence of efficacy in fibromyalgia, such as amitriptyline, cannabinoids, and tramadol, even a larger proportion of patients with fibromyalgia (66%) reported using nociceptive painkillers (non-steroidal analgesics and paracetamol) with limited/no evidence of efficacy. Our findings are in line with previously published reports on pain medication in motor and seizure subtypes of FND, which reported up to 50% of individuals on pain medication [17,41,42]. The increased use of nociceptive pain medications may reflect frequent misdiagnosis and focus on local pain problems and limited recognition of the nociplastic nature of chronic pain conditions, as well as insufficient patient education regarding chronic nociplastic pain and non-pharmacological treatment options. Additional contributing factors may include cultural beliefs, lack of education of health care professionals, the absence of national treatment guidelines for fibromyalgia, and the off-label status of effective medications.

Our study highlights the importance of widespread pain assessment and its adequate

management in the FMD population. Pain is associated with greater FND severity, reduced quality of

life, and worse prognosis [5,7,20,43]. Diagnosis of fibromyalgia in FMD has numerous implications

for the management, including provision of pain education and adjustment of self-management plan,

which should focus on maintaining activity, not symptom relief, lower-grade exercise, and triage for

specialised pain care [10]. FSS is a reliable negative prognostic factor for outcomes for several types

of interventions, including hip surgery or persistent pelvic pain following hysterectomy [44,45].

These findings can also apply to people with FMD and guide clinical decision making and planning,

such as avoiding overmedication, consulting multiple specialists and unnecessary surgeries for local

pain problems in people with fibromyalgia through multidisciplinary care.  There are international

guidelines and other evidence-based recommendations for pharmacological and non-pharmacological

management of fibromyalgia, including education, physical activity/rehabilitation techniques and

other non-invasive treatments interventions based on comorbidities such as mood and sleep disorders,

which can also be used for patients with FMD in the absence of specific recommendations [46–48].

Treatments potentially effective for pain, such as physical therapy and behavioural interventions,

mostly failed to improve pain in trials with people with FMD  [5,49–51]. One recent study combining

physiotherapy and cognitive behavioural therapy reported improvement in pain [52]. Identifying FMD

patients with comorbid symptoms such as fibromyalgia could help guide clinicians toward

recommending brain–mind–body approaches, which may be more appropriate than standard motor

rehabilitation alone.

Functional neurological disorder and other somatic syndrome disorders including

fibromyalgia are associated with alterations in the functioning of brain networks and are now believed

to share underlying pathophysiological mechanisms [39,53]. Recent theoretical models based on

predictive coding accounts of brain function suggest functional symptoms arise from the development

of abnormal predictions about motor and sensory states, including pain, driven by an abnormal

allocation of attention [39,53]. These models are symptom type agnostic and suggest that a common

underlying mechanism can explain motor, sensory, cognitive, and interoceptive manifestations.

Despite growing clinical and scientific evidence for a unified mechanism, pain, fatigue, and other

non-motor symptoms in FND remain separately classified in DSM-5 as somatic symptom disorder

and chronic pain syndrome [23]. A diagnostic split also exists in the 11th revision of the International

Statistical Classification of Diseases and Related Health Problems (ICD-11), where FMD appears in

both the Neurology (08) and Psychiatry chapters (06), while chronic widespread pain is coded

separately under Symptoms, signs or clinical findings, not elsewhere classified (21) [54]. The high

prevalence of fibromyalgia in FMD further challenges this classification divide and underscores the

need for more integrated diagnostic frameworks.

There are limitations to this study, including bias inherent to a single-centre epidemiological

study. People with more severe FMD are likely to be followed in a tertiary centre with specialised

FMD service, which results in a potential overestimation of fibromyalgia frequency in the FMD

cohort derived from such a centre. We did not assess whether fibromyalgia developed before or after

the onset of motor symptoms, nor the time interval between the two. Additionally, we did not

systematically ask patients whether they had undergone a rheumatological assessment. These

limitations should be addressed in future studies. A multicenter study from different countries would

increase sample size and diversity, reduce selection bias, provide a more representative sample of the

FMD population, and allow for examining cross-cultural differences. A recent review on pain in FND

suggested that pain is more common in FMD than in functional seizures [5]. Future studies should

assess the prevalence of fibromyalgia in functional seizures.

**Conclusions**

Fibromyalgia was highly prevalent in FMD and was associated with more severe motor

symptoms, higher medication use, and lower quality of life. This finding may have implications for

the assessment and management of FMD patients with comorbid pain. Systematic screening for

fibromyalgia may be warranted in FMD clinics, particularly in specialized centres, to ensure

appropriate multidisciplinary care and tailored treatment strategies.

Acknowledgements

Funding: This study was supported by the Czech Ministry of Health (NW24-04-00456 and MH CZ–

DRO-VFN00064165) and National Institute for Neurological Research (Programme EXCELES, ID

**Author roles:**

1. Research project: A. Conception, B. Organization, C. Execution;

2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique;

3. Manuscript: A. Writing of the first draft, B. Review and Critique;

4. Funding: A. Obtaining Funding.

**Tereza Serranová:** 1A, 1B, 1C, 2A, 2C, 3A, 3B, 4A

**Lucia Nováková:** 1A, 1B, 1C

**Martin Jirásek:** 1C, 2B, 3A

**Barbora Křupková:** 1C, 2B, 3A

**Evžen Růžička:** 3A, 3B

**Michele Tinazzi:** 3A, 3B

**Tomáš Sieger:** 2A, 2B, 2C, 3A

**Disclosures**

**Tereza Serranová**

**Stock Ownership in medically-related fields:** None

**Intellectual Property Rights:** None

**Consultancies:** None Expert Testimony: None

**Advisory Boards:** None

**Employment:** Department of Neurology and Centre of Clinical Neuroscience, Charles
University in Prague, 1st Faculty of Medicine and General University Hospital in Prague,
Czech Republic

**Partnerships:** None

**Contracts:** None

**Honoraria:** None

**Royalties:** None
**Grants:** Ministry of Health of the Czech Republic

**Other:** None

**Lucia Nováková**

**Stock Ownership in medically-related fields:** None

**Intellectual Property Rights:** None

**Consultancies:** None Expert Testimony: None

**Advisory Boards:** None
**Employment:** Department of Neurology and Centre of Clinical Neuroscience, Charles
University in Prague, 1st Faculty of Medicine and General University Hospital in Prague,
Czech Republic

**Partnerships:** None

**Contracts:** None

**Honoraria:** None

**Royalties:** None
**Grants:** Ministry of Health of the Czech Republic

**Other:** None

**Martin Jirásek**

**Stock Ownership in medically-related fields:** None

**Intellectual Property Rights:** None

**Consultancies:** None Expert Testimony: None

**Advisory Boards:** None

**Employment:** Department of Department of Rehabilitation and Sports Medicine, Charles

University in Prague, 2$^{nd}$ Faculty of Medicine and University Hospital Motol in Prague,

Czech Republic

**Partnerships:** None

**Contracts:** None

**Honoraria:** None

**Royalties:** None

**Grants:** Ministry of Health of the Czech Republic

**Other:** None

**Barbora Křupková**

**Stock Ownership in medically-related fields:** None

**Intellectual Property Rights:** None

**Consultancies:** None Expert Testimony: None

**Advisory Boards:** None

**Employment:** Department of Neurology and Centre of Clinical Neuroscience, Charles

University in Prague, 1$^{st}$ Faculty of Medicine and General University Hospital in Prague,

Czech Republic

**Partnerships:** None

**Contracts:** None

**Honoraria:** None

**Royalties:** None

**Grants:** Ministry of Health of the Czech Republic

**Other:** None

**Evžen Růžička**

**Stock Ownership in medically-related fields:** None

**Intellectual Property Rights:** None

**Consultancies:** None Expert Testimony: None

**Advisory Boards:** None

**Employment:** Department of Neurology and Centre of Clinical Neuroscience, Charles

University in Prague, 1$^{st}$ Faculty of Medicine and General University Hospital in Prague,

Czech Republic

**Partnerships:** None

**Contracts:** None

**Honoraria:** None

**Royalties:** None

**Grants**: Ministry of Health of the Czech Republic

**Other:** None

**Michele Tinazzi**

**Stock Ownership in medically-related fields:** None

**Intellectual Property Rights:** None

**Consultancies:** None Expert Testimony: None

**Advisory Boards:** None

**Employment:** Department of Neurosciences, Biomedicine and Movement Sciences,

University of Verona, Verona, Italy

**Partnerships:** None

**Contracts:** None

**Honoraria:** personal fees from Abbvie, Bial, Chiesi Farmaceutici, Zambon, and the

Movement Disorders Society.

**Royalties:** None

**Grants**: Italian Ministry of Health, University of Verona, and the Verona Brain Research

Foundation

**Other:** None

**Tomáš Sieger**

**Stock Ownership in medically-related fields:** None

**Intellectual Property Rights:** None

**Consultancies:** None Expert Testimony: None

**Advisory Boards:** None

**Employment:** Department of Cybernetics, Faculty of Electrical Engineering, Czech

Technical University in Prague, Czech Republic and Department of Neurology and Centre of

Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General

University Hospital in Prague, Czech Republic

**Partnerships:** None

**Contracts:** None

**Honoraria:** None

**References:**

1.    Hallett M, Aybek S, Dworetzky BA, McWhirter L, Staab JP, Stone J. Functional neurological

disorder: new subtypes and shared mechanisms. Lancet Neurol. 2022;21: 537–550.

doi:10.1016/S1474-4422(21)00422-1

2.    O'Mahony B, Nielsen G, Baxendale S, Edwards MJ, Yogarajah M. Economic Cost of Functional

Neurologic Disorders: A Systematic Review. Neurology. 2023;101: e202–e214.

doi:10.1212/WNL.0000000000207388

3.    Věchetová G, Slovák M, Kemlink D, et al. The impact of non-motor symptoms on the health-

related quality of life in patients with functional movement disorders. J Psychosom Res.

2018;115: 32–37. doi:10.1016/j.jpsychores.2018.10.001

4.    Carle-Toulemonde G, Goutte J, Do-Quang-Cantagrel N, Mouchabac S, Joly C, Garcin B. Overall

comorbidities in functional neurological disorder: A narrative review. Encephale. 2023;49: S24–

S32. doi:10.1016/j.encep.2023.06.004

5.    Steinruecke M, Mason I, Keen M, et al.Pain and functional neurological disorder: a systematic

review and meta-analysis. J Neurol Neurosurg Psychiatry. 2024;95: 874–885. doi:10.1136/jnnp-

2023-332810

6.    Gelauff J, Stone J, Edwards M, Carson A. The prognosis of functional (psychogenic) motor

symptoms: a systematic review. J Neurol Neurosurg Psychiatry. 2014;85: 220–226.

doi:10.1136/jnnp-2013-305321

7.    Forejtová Z, Serranová T, Sieger T, et al. The complex syndrome of functional neurological

disorder. Psychol Med. 2023;53: 3157–3167. doi:10.1017/S0033291721005225

8.    Gilmour GS, Nielsen G, Teodoro T, et al. Management of functional neurological disorder. J

Neurol. 2020;267: 2164–2172. doi:10.1007/s00415-020-09772-w

9.    Serranová T, Di Vico I, Tinazzi M. Functional Movement Disorder: Assessment and Treatment.

Neurol Clin. 2023;41: 583–603. doi:10.1016/j.ncl.2023.02.002

10.   Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update on clinical

characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16: 645–660.

doi:10.1038/s41584-020-00506-w

11.   Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia.

Patient Educ Couns. 2008;73: 114–120. doi:10.1016/j.pec.2008.06.005

12.   Butler M, Shipston-Sharman O, Seynaeve M, et al. International online survey of 1048

individuals with functional neurological disorder. Eur J Neurol. 2021;28: 3591–3602.

doi:10.1111/ene.15018

13.   Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path

forward. J Pain. 2013;14: 1539–1552. doi:10.1016/j.jpain.2013.08.007

14.   Kravitz HM, Katz RS. Fibrofog and fibromyalgia: a narrative review and implications for

clinical practice. Rheumatol Int. 2015;35: 1115–1125. doi:10.1007/s00296-014-3208-7

15.   Wolfe F, Clauw DJ, Fitzcharles M-A, et al. 2016 Revisions to the 2010/2011 fibromyalgia

diagnostic    criteria.    Semin    Arthritis    Rheum.    2016;46:    319–329.

doi:10.1016/j.semarthrit.2016.08.012

16.   Tinazzi M, Geroin C, Marcuzzo E, et al. Functional motor phenotypes: to lump or to split? J

Neurol. 2021;268: 4737–4743. doi:10.1007/s00415-021-10583-w

17.   Stephen CD, Perez DL, Chibnik LB, Sharma N. Functional dystonia: A case-control study and

risk prediction algorithm. Ann Clin Transl Neurol. 2021;8: 732–748. doi:10.1002/acn3.51307

18. Driver-Dunckley E, Stonnington CM, Locke DE, Noe K. Comparison of Psychogenic Movement

Disorders and Psychogenic Nonepileptic Seizures: Is Phenotype Clinically Important?

Psychosomatics. 2011;52: 337–345. doi:10.1016/j.psym.2011.01.008

19. Geroin C, Stone J, Camozzi S, Demartini B, Gandolfi M, Tinazzi M. Triggers in functional

motor disorder: a clinical feature distinct from precipitating factors. J Neurol. 2022;269: 3892–

3898. doi:10.1007/s00415-022-11102-1

20. Stone J, Warlow C, Deary I, Sharpe M. Predisposing Risk Factors for Functional Limb

Weakness: A Case-Control Study. J Neuropsychiatry Clin Neurosci. 2020;32: 50–57.

doi:10.1176/appi.neuropsych.19050109

21. Matin N, Young SS, Williams B, et al. Neuropsychiatric associations with gender, illness

duration, work disability, and motor subtype in a U.s. functional neurological disorders clinic

population. J Neuropsychiatry Clin Neurosci. 2017;29: 375–382.

doi:10.1176/appi.neuropsych.16110302

22. Gupta A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol. 2009;22: 430–436.

doi:10.1097/WCO.0b013e32832dc169

23. Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World

Psychiatry. 2013;12: 92–98. doi:10.1002/wps.20050

24. Aybek S, Perez DL. Diagnosis and management of functional neurological disorder. BMJ.

2022;376: o64. doi:10.1136/bmj.o64

25. Nielsen G, Ricciardi L, Meppelink AM, Holt K, Teodoro T, Edwards M. A Simplified Version

of the Psychogenic Movement Disorders Rating Scale: The Simplified Functional Movement

Disorders Rating Scale (S-FMDRS). Mov Disord Clin Pract. 2017;4: 710–716.

doi:10.1002/mdc3.12475

26.  Wolfe F, Clauw DJ, Fitzcharles M-A, et al. The American College of Rheumatology preliminary

diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res

(Hoboken). 2010;62: 600–610. doi:10.1002/acr.20140

27.  Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating

the severity of somatic symptoms. Psychosom Med. 2002;64: 258–266. doi:10.1097/00006842-

200203000-00008

28.  Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales

and   preliminary   tests   of   reliability   and   validity.   Med   Care.   1996;34:   220–233.

doi:10.1097/00005650-199603000-00003

29.  Hollander M, Wolfe DA, Chicken E. Nonparametric Statistical Methods. John Wiley & Sons;

2013.

Available:https://books.google.com/books/about/Nonparametric_Statistical_Methods.html?

hl=&id=Y5s3AgAAQBAJ

30.  Holm S. A Simple Sequentially Rejective Multiple Test Procedure. Scandinavian Journal of

Statistics. 1979;6: 65–70. Available: https://www.jstor.org/stable/4615733

31.  Häuser W, Sarzi-Puttini P, Fitzcharles M-A. Fibromyalgia syndrome: under-, over- and

misdiagnosis.   Clin   Exp   Rheumatol.   2019;37   Suppl   116:   90–97.   Available:

https://pubmed.ncbi.nlm.nih.gov/30747096/

32.  Ramírez-Morales R, Bermúdez-Benítez E, Martínez-Martínez L-A, Martínez-Lavín M. Clinical

overlap between fibromyalgia and myalgic encephalomyelitis. A systematic review and meta-

analysis. Autoimmun Rev. 2022;21: 103129. doi:10.1016/j.autrev.2022.103129

33.  Duffield SJ, Miller N, Zhao S, Goodson NJ. Concomitant fibromyalgia complicating chronic

inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2018;57:

1453–1460. doi:10.1093/rheumatology/key112

34.  Ray JC, Matharu M, Hutton E. Relationship of migraine and other forms of chronic pain. Handb
Clin Neurol. 2024;199: 517–524. doi:10.1016/B978-0-12-823357-3.00027-6

35.  Henningsen P, Hausteiner-Wiehle C, Häuser W. Migraine in the context of chronic primary pain,
chronic overlapping pain disorders, and functional somatic disorders: A narrative review.
Headache. 2022;62: 1272–1280. doi:10.1111/head.14419

36.  Finkelstein SA, Diamond C, Carson A, Stone J. Incidence and prevalence of functional
neurological disorder: a systematic review. J Neurol Neurosurg Psychiatry. 2025;96: 383–395.
doi:10.1136/jnnp-2024-334767

37.  Mason I, Renée J, Marples I, et al. Functional neurological disorder is common in patients
attending chronic pain clinics. Eur J Neurol. 2023;30: 2669–2674. doi:10.1111/ene.15892

38.  Watson NF, Buchwald D, Goldberg J, Noonan C, Ellenbogen RG. Neurologic signs and
symptoms in fibromyalgia. Arthritis Rheum. 2009;60: 2839–2844. doi:10.1002/art.24772

39.  Edwards MJ, Adams RA, Brown H, Pareés I, Friston KJ. A Bayesian account of "hysteria."
Brain. 2012;135: 3495–3512. doi:10.1093/brain/aws129

40.  Gelauff JM, Rosmalen JGM, Gardien J, Stone J, Tijssen MAJ. Shared demographics and
comorbidities in different functional motor disorders. Parkinsonism Relat Disord. 2020;70: 1–6.
doi:10.1016/j.parkreldis.2019.11.018

41.  Gazzola DM, Carlson C, Rugino A, Hirsch S, Starner K, Devinsky O. Psychogenic nonepileptic
seizures and chronic pain: a retrospective case-controlled study. Epilepsy Behav. 2012;25: 662–
665. doi:10.1016/j.yebeh.2012.10.008

42.  Hantke NC, Doherty MJ, Haltiner AM. Medication use profiles in patients with psychogenic
nonepileptic seizures. Epilepsy Behav. 2007;10: 333–335. doi:10.1016/j.yebeh.2006.11.014

43.  Lagrand T, Tuitert I, Klamer M, et al. Functional or not functional; that's the question: Can we
predict the diagnosis functional movement disorder based on associated features? Eur J Neurol.

2021;28: 33–39. doi:10.1111/ene.14488

44.  Brummett CM, Urquhart AG, Hassett AL, et al. Characteristics of fibromyalgia independently

predict poorer long-term analgesic outcomes following total knee and hip arthroplasty: Poorer

tka and Tha outcomes in patients with Fm characteristics. Arthritis Rheumatol. 2015;67: 1386–

1394. doi:10.1002/art.39051

45.  As-Sanie S, Till SR, Schrepf AD, et al. Incidence and predictors of persistent pelvic pain

following hysterectomy in women with chronic pelvic pain. Am J Obstet Gynecol. 2021;225:

568.e1–568.e11. doi:10.1016/j.ajog.2021.08.038

46.  Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the

management of fibromyalgia. Ann Rheum Dis. 2017;76: 318–328. doi:10.1136/annrheumdis-

2016-209724

47.  Fitzcharles M-A, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. Nociplastic pain:

towards an understanding of prevalent pain conditions. Lancet. 2021;397: 2098–2110.

doi:10.1016/S0140-6736(21)00392-5

48.  Skelly AC, Chou R, Dettori JR, et al. Noninvasive Nonpharmacological Treatment for Chronic

Pain: A Systematic Review Update. Rockville (MD): Agency for Healthcare Research and

Quality (US); 2020. Available: https://www.ncbi.nlm.nih.gov/pubmed/32338846

49.  Nielsen G, Stone J, Lee TC, et al. Specialist physiotherapy for functional motor disorder in

England and Scotland (Physio4FMD): a pragmatic, multicentre, phase 3 randomised controlled

trial. Lancet Neurol. 2024;23: 675–686. doi:10.1016/S1474-4422(24)00135-2

50.  Reuber M, Burness C, Howlett S, Brazier J, Grünewald R. Tailored psychotherapy for patients

with functional neurological symptoms: a pilot study. J Psychosom Res. 2007;63: 625–632.

doi:10.1016/j.jpsychores.2007.06.013

51.  Gandolfi M, Riello M, Bellamoli V, et al. Motor and non-motor outcomes after a rehabilitation

program for patients with Functional Motor Disorders: A prospective, observational cohort
study. NeuroRehabilitation. 2021;48: 305–314. doi:10.3233/NRE-201617

52.  Macías-García D, Méndez-Del Barrio M, Canal-Rivero M, et al. Combined Physiotherapy and
Cognitive Behavioral Therapy for Functional Movement Disorders: A Randomized Clinical
Trial. JAMA Neurol. 2024;81: 966–976. doi:10.1001/jamaneurol.2024.2393

53.  Van den Bergh O, Witthöft M, Petersen S, Brown RJ. Symptoms and the body: Taking the
inferential    leap.    Neurosci    Biobehav    Rev.    2017;74:    185–203.
doi:10.1016/j.neubiorev.2017.01.015

54.  World Health Organization. International statistical classification of diseases and related health
problems (11th Edition.). 2019. Available: https://icd.who.int/

Table 1. Demographic and clinical characteristics in FMD patients with and without fibromyalgia

| | FMD with FM (n = 62) | FMD without FM (n = 77) | Test Statistics | P-value |
|---|---|---|---|---|
| Sex | 50 F, 12 M | 65 F, 12 M | Fisher test (n/a) | 0.65 |
| Age (years) | 44.9 (SD 10.5), range 18–72 | 44.4 (SD 12.0), range 15–65 | $t$ (137) = 0.248 | 0.81 |
| Disease onset (years) | 37.0 (SD 12.1), range 7–69 | 38.2 (SD 11.2), range 13–58 | $t$ (137) = 0.60 | 0.55 |
| Disease duration (years) | Median 5 (IQR 7), range 1–34 | Median 4 (IQR 5), range 0–40 | $W$ = 1953.5 | 0.065 |

616 Abbreviations: FM – Fibromyalgia, FMD – Functional Motor Disorder, IQR – Interquartile Range,

617     n/a – Not Applicable, SD – Standard Deviation, W – Wilcoxon test statistic

618    Table 2 Health-related quality of live and motor symptom measures in FMD patients with and without

619    fibromyalgia

| | FMD with FM (n = 62) | FMD without FM (n = 77) | Test Statistics | P-value (corrected) |
|---|---|---|---|---|
| **SF-12 (median [IQR], range)** | 20 [6], 12–32 | 24 [6], 14–42 | $W$ = 3480 | **< 0.001** |
| **Main motor phenotype (n)** | | | | |
| Tremor | 17 | 22 | Fisher test (n/a) | 1 |
| Gait disorder and instability | 23 | 13 | Fisher test (n/a) | 0.065 |
| Dystonia | 7 | 8 | Fisher test (n/a) | 1 |
| Weakness | 13 | 32 | Fisher test (n/a) | 0.065 |
| Myoclonus | 2 | 1 | Fisher test (n/a) | 1 |
| Speech and swallowing disorder | 0 | 1 | Fisher test (n/a) | 1 |
| Parkinsonism | 0 | 0 | n/a | n/a |
| **Main or additional motor phenotype (n)** | | | | |
| Tremor | 38 | 42 | Fisher test (n/a) | 1 |
| Gait disorder and instability | 49 | 47 | Fisher test (n/a) | 0.19 |
| Dystonia | 23 | 20 | Fisher test (n/a) | 1 |
| Weakness | 47 | 52 | Fisher test (n/a) | 1 |
| Myoclonus | 7 | 4 | Fisher test (n(a) | 1 |
| Speech and swallowing | 7 | 9 | Fisher test (n/a) | 1 |

| | FMD with FM (n = 62) | FMD without FM (n = 77) | Test Statistics | P-value (corrected) |
|---|---|---|---|---|
| disorder | | | | |
| Parkinsonism | 1 | 0 | Fisher test (n/a) | 1 |
| **S-FMDRS score (median, range)** | 14.5 (0–34) | 10 (0–31) | *W* = 1707 | **0.016** |
| **Gait disturbances (%)** | 77% | 56% | Fisher test (n/a) | **0.026** |
| **Use of gait aids (%)** | Wheelchair: 8% Crutch: 26% | Wheelchair: 3%, Crutch: 13% | *W* = 2832.5 | **0.026** |
| **No. of motor phenotypes (median [IQR], range)** | 3 [1], (1–6) | 2 [1], (1–6) | *W* = 1796.5 | **0.026** |
| **SMSS (median [IQR], range)** | 7.5 [3], 1–10 | 5 [4], 0–10 | *W* = 1230.5 | **< 0.001** |

621 Abbreviations: FM – Fibromyalgia, FMD – Functional Motor Disorder, HRQoL – Health-Related

622 Quality of Life, IQR – Interquartile Range, n/a – Not Applicable, S-FMDRS –The Simplified

623 Functional Movement Disorder Rating Scale, SF-12 – 12-Item v2 Short Form Health Survey SMSS –

624 Subjective Motor Symptom Severity, W – Wilcoxon test statistic

625 Significant results are presented in bold.

631    Table 3. Medication and comorbidities in FMD patients with and without fibromyalgia

|  | FMD with FM (n = 62) | FMD without FM (n = 77) | Test Statistics | P-value (corrected) |
|---|---|---|---|---|
| Medication | | | | |
| Number of medications (median [IQR], range) | 2 [2], 0-7 (most frequent: 2 meds) | 1 [3], 0-8 (most frequent: 0 meds) | $W$ = 1712 | **0.012** |
| Use of FM-specific agents (amitriptyline, cannabinoids, tramadol) (%) | 58% | 32% | $W$ = 1771 | **0.012** |
| Use of nociceptive painkillers (NSAIDs, paracetamol) (%) | 66% | 38% | $W$ = 1784.5 | **0.012** |
| Other medication (antidepressants, opioids) | 47% | 53% | $W$ = 2182.5 | 0.36 |
| Comorbidities | | | | |
| Total number of comorbidities (median [IQR], range) | 3 [2], 0–9 | 3 [2], 0–7 | $W$ = 1926 | 0.24 |
| Number of internal comorbidities (median [IQR], range) | 2 [2], 0–7 | 1 [1], 0–5 | $W$ = 2039.5 | 0.38 |
| Number of neurological | 0 [1], 0–2 | 0 [0], 0–2 | $W$ = 2243 | 0.85 |

| comorbidities (median [IQR], range) | | | | |
|---|---|---|---|---|
| Migraine prevalence (%) | 55% | 39% | Fisher test (n/a) | 0.35 |
| RLS prevalence (%) | 37% | 38% | Fisher test (n/a) | 1 |

634 Abbreviations: FM – Fibromyalgia, FMD – Functional Motor Disorder, IQR – Interquartile Range,

635 n/a – Not Applicable, NSAIDs – Non-Steroidal Anti-Inflammatory Drugs, RLS – Restless Legs

636 Syndrome, W – Wilcoxon test statistic

637 Significant results are presented in bold.

**Supplementary Tables**

Table S1. Frequencies of Neurological Comorbidities in FMD Patients (n = 139)

|  | n |
|---|---|
| Radicular pain | 10 |
| Stroke | 5 |
| Neuromuscular disorder | 5 |
| Traumatic brain injury | 5 |
| Polyneuropathy | 4 |
| Essential tremor | 3 |
| Cranial nerve disorder (i.e. facial nerve palsy) | 3 |
| Dystonia | 2 |
| Epilepsy | 2 |
| History of infectious disease of nervous system | 1 |
| Demyelinating disease | 1 |

Table S2. Frequencies of comorbid physical illnesses in FMD Patients (n = 139)

|  | n |
|---|---|
| Obesity | 44 |
| Arterial hypertension | 32 |
| Asthma or other respiratory disorder | 26 |
| Thyroid disorder | 25 |
| Rheumatological disorder | 21 |
| Dyslipidemia | 18 |
| Cardiovascular disease | 17 |
| Gastrointestinal disorder | 15 |
| Gynecological and reproductive disorders | 10 |
| Diabetes mellitus | 8 |
| History of malignancy | 5 |
| Autoimmune disorder | 4 |